Welcome to our dedicated page for FOXO TECHNOLOGIES news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO TECHNOLOGIES stock.
FOXO Technologies Inc. operates healthcare-related subsidiaries that include a critical access acute care hospital, a behavioral health treatment business, a biotechnology subsidiary and Vector BioSource, a biospecimen and data sourcing provider for biotechnology, clinical research and pharmaceutical research customers.
Company news commonly covers clinical-capability additions at Big South Fork Medical Center, swing-bed and specialty-care arrangements, license and operating updates for Myrtle Recovery Centers, acquisition activity, capital-structure actions and trading-status developments for FOXO common stock on the OTC market.
FOXO Technologies (NYSE American: FOXO) has signed a non-binding agreement to acquire an assisted living and memory care facility in South Florida for $22 million. The facility features 87 licensed units for assisted living and memory care services. The purchase structure includes $5 million in non-convertible preferred stock, with a portion being milestone-based.
The company is also finalizing a previously announced acquisition of Vector Biosource, Inc., and pursuing expansion in assisted living and behavioral health sectors through its Myrtle Recovery Centers subsidiary. If current non-binding agreements are completed, FOXO will add over 350 units to its healthcare services portfolio. The company expects to file its Q2 2025 10-Q by August 14, projecting improved revenues and profitability.
FOXO Technologies Inc. (NYSE American: FOXO) announced that its Big South Fork Medical Center in Oneida, Tennessee has established a Performance Network Agreement with Covenant Health to provide swing bed services. The agreement enables the critical access designated rural hospital to offer post-acute care services to patients from Covenant Health's network, which serves greater Knoxville and East Tennessee.
The partnership aims to help patients who no longer require acute care to recover closer to their homes and families. This strategic move aligns with FOXO's organic growth strategy to increase net revenues at the hospital by expanding its service offerings through the Covenant Health performance network.
FOXO Technologies (NYSE American: FOXO) announced that its behavioral health subsidiary, Myrtle Recovery Centers, has successfully renewed its operating license for its Oneida, Tennessee facility for another year. The renewal was granted by Tennessee's Department of Mental Health and Substance Abuse Services following a successful annual inspection.
The facility, which provides alcohol and drug residential treatment services, is currently operating at full capacity with a waiting list for future admissions. Management is actively exploring strategic expansion options, including opening a second location and potential acquisitions in the behavioral health sector.
FOXO Technologies Inc. (NYSE American: FOXO) has announced its Board's approval to pursue the spin-off of its subsidiary, FOXO Labs, Inc., which specializes in epigenetics technology. The subsidiary owns Patent No. 11,817,214 for machine learning models that determine biochemical states using DNA epigenetic data.
FOXO Labs utilizes saliva-based epigenetic biomarkers to provide health, lifestyle, and longevity insights, eliminating the need for invasive blood and urine collection. The company is developing an AI-powered health coaching system that combines wearable data with epigenetic analysis to deliver personalized wellness guidance.
The spin-off aims to create a subscription-based revenue model for personal health and longevity, with FOXO Technologies maintaining partial ownership while allowing shareholders to benefit from direct ownership in FOXO Labs.
FOXO Technologies (NYSE American: FOXO) has announced a 1-for-1.99 reverse stock split of its Class A common stock, effective July 27, 2025, at 4:01 PM ET. The stock will begin trading on a split-adjusted basis on July 28, 2025, under the same symbol but with a new CUSIP number.
The reverse split was approved on June 23, 2025, by a majority stockholder and aims to ensure compliance with NYSE American's continued listing requirement of maintaining a stock price above $0.10 per share. Fractional shares will be rounded up to the next whole number, and all outstanding securities, including preferred stock, debt, options, warrants, and equity incentive plans, will be proportionally adjusted.
FOXO Technologies Inc. (NYSE American: FOXO) announced that its behavioral health subsidiary, Myrtle Recovery Centers, has secured approval for Scott County Opioid Abatement Funds for a second consecutive year. The funding, effective July 1, 2025, will support care for uninsured patients from Scott County at the company's Oneida, Tennessee facility.
The facility is currently operating at full capacity with a patient waiting list, demonstrating strong demand for its services. Myrtle's CEO Robert Merritt highlighted this as validation of their clinical team's quality of care. FOXO's CEO Seamus Lagan indicated plans for expansion through organic growth and acquisitions, expecting Myrtle to become a significant revenue contributor to FOXO in the future.
FOXO Technologies (NYSE American: FOXO) has designated a new Series E Cumulative Redeemable Secured Preferred Stock to support its acquisition strategy. The Series E Preferred Stock features include a $25.00 per share stated value, 2.5% annual cash dividend (paid semi-annually), 5.0% annual common stock dividend (paid semi-annually), and security interest in FOXO Acquisition Corporation.
The company plans to use this preferred stock as both acquisition currency and for capital raising, with intentions to have it publicly listed with its own trading symbol. CEO Seamus Lagan emphasized this non-dilutive funding mechanism's potential to increase net revenues and cash flow through strategic acquisitions.